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Background: In patients with hypertriglyceridemia, non-high density lipoprotein cholesterol (nonHDL-C) is
a targeted goal. However, apoprotein B100 (apoB) may be superior in predicting cardiovascular risk so we
assessed the utility of an apoB-based.
Methods: New patients (n=125) who had both apoB and standard lipids measured on the same day were
included andwe determined the concordances of having achieved goal lipid levels based upon proposed apoB
versus nonHDL-C (ATP III) targets in patients with elevated TG (>150 mg·dl−1) levels.
Results: Although apoB was correlated with nonHDL-C (r= 0.47, p<0.001), the tests had only a fair level of
agreementwhen categorizing thepercentageof patients achieving lipid goals for their degreeof cardiovascular
risk (κ = 0.22). Among patients with an elevation in nonHDL-C above ATP III goals, between 12–42% had
achieved target apoB. On the contrary, between 44–50% of patients were found to be at nonHDL-C but not
apoB target. The results were not substantively altered if the analyses were confined to patients with TG values
between 200–499 mg·dl−1, rather than all patients with TG levels >150 mg·dl−1, as specifically outlined in
ATP III guidelines. In total, >50% of all subjects would have been treated either more or less aggressively
following an apoB-based therapeutic algorithm.
Conclusions: Our findings confirm that the majority of patients referred with hypertriglyceridemia would be
managed differently by following an apoB-based treatment algorithm compared to ATP III guidelines. Although
many patients would be candidates for more intense therapy, many would be treated less aggressively.
Introduction
Plasma apoprotein B100 (apoB) represents the total con-
centration of lipoproteins that play a pathological role
in atherosclerosis (eg low density lipoprotein [LDL],
very low density lipoprotein remnants).1,2 Due to varia-
tions in lipoprotein composition, substantial differences in
apoB can occur among patients despite a similar LDL-
cholesterol (LDL-C). Targeting only LDL-C does not ade-
quately treat all atherogenic lipoprotein subfractions, nor
does it address elevated lipoprotein particle numbers3. Due
to these shortcomings, the National Cholesterol Educa-
tion Program Adult Treatment Panel (ATP III) proposed
using a secondary goal beyond LDL-C in patients with
hypertriglyceridemia. The guidelines propose targeting
non-high-density lipoprotein cholesterol (non-HDL-C), a
better cardiovascular (CV) risk marker in patients with
high triglyceride (TG) levels,4,5 as a clinically useful sur-
rogate marker of apoB. However, discordances between
non-HDL-C and apoB have been shown to occur in popula-
tion studies.6,7,8
The apoB concentration is more biologically linked
to the genesis of atherosclerosis than is the simple
level of cholesterol within any subset of particles.1 Some
epidemiological studies confirm that apoB may be superior
to both LDL-C and non-HDL-C in predicting CV risk.1,6,9,10
This possible inferiority of non-HDL-C may be due to several
factors, including the fact that much of the cholesterol
content within this calculated fraction often falls within
larger non-atherogenic particles.1 Several studies have also
suggested that any LDL-C, non-HDL-C, or TG value may
not provide additional CV risk information among patients
in whom apoB is known.1,8,9
The prevalence of obesity is growing at a prodigious
rate11 and thus both moderate (150–500 mg·dl−1) and
severe (>500 mg·dl−1) hypertriglyceridemia are now com-
mon findings. Therefore, the ATP III recommendation to
target treatment of non-HDL-C in such patients is becom-
ing increasingly more relevant to clinical practice.4 This
often leads to the requirement to add more medications
(e.g., fibrate, niacin, fish oil) to first-line statin treatment.
However, due to weaknesses of non-HDL-C, some experts
have suggested targeting apoB as an alternative strategy.12
Although unproven at this time, the epidemiological studies
do provide some evidence to support the notion that it may
be valid to manage patients based solely upon apoB targets,
regardless of their TG or non-HDL-C values.1,8,9 In popu-
lation surveys, this approach has already been shown to
identify a substantial fraction of patients who may possibly
be undertreated by using conventional lipid goals.8
The University of Michigan Lipid Management program
is a tertiary care specialty lipid disorders clinic that receives
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Clinical Investigations continued
referrals from a large geographic area. A sizeable proportion
of our patients are referred specifically for management
of hypertriglyceridemia. Although apoB and non-HDL-C
have been shown to be discordant in population studies,8
we are not aware of this relationship being explicitly
characterized among patients referred to a specialty lipid
clinic. Given the complexity of lipid disorders, the severity
of hypertriglyceridemia (e.g., many patients with TG values
>1,000 mg·dl−1) and the nature of the referral biases to our
clinic, findings from other cohorts cannot be generalized
to our unique patient network. Thus, the purpose of this
study was to assess how an apoB-based treatment algorithm
might alter our management decisions compared with ATP
III guidelines, specifically among our new patient referrals
prior to utilizing apoprotein values for patient care. We
hypothesized that basing treatment targets upon apoB,
rather than non-HDL-C (per ATP III guidelines), would
result in substantial differences in subsequent management.
While it has been suggested that apoB-based management
would identify a large percentage of patients that are
undertreated,8 we also expressly sought to quantify the
number of individuals with high TG values that would be
treated less aggressively (i.e., those who have apoB at goal
despite an elevated non-HDL-C). We believed that this may
represent an underappreciated, sizeable group of patients
with a less atherogenic form of hypertriglyceridemia who
could avoid additional medications (possibly appropriately
so) by targeting only apoB goals.
Methods
This study was approved by the Institutional Review Board
of the University of Michigan. We performed a retrospective
review of all new patient visits (ie initial evaluation) to the
Preventive Cardiology and Lipid Management Clinic at the
University of Michigan during the past 2 years. All subjects
who had fasting traditional lipids plus apoB measured (at the
same visit) at the University of Michigan Hospital Clinical
Chemistry Laboratory and in whom we were able to identify
their ATP III goal lipid values were identified. We then
included in the subsequent analyses only subjects with ele-
vated TG values above optimal (>150 mg·dl−1). Secondarily,
we also evaluated patients with TG values >200 mg·dl−1, and
additionally, specifically between 200–499 mg·dl−1, where
further treatments options are based upon non-HDL-C goals
(not LDL-C) as specifically recommended by ATP III. This
is the scenario where apoB may be most useful,1 and where
direct comparisons with non-HDL-C are meaningful. Thus,
concordances with LDL-C levels, as has been reported
elsewhere,7 are not clinically meaningful among our study
patients with high TG values, as non-HDL-C is the ATP III
lipid goal and in most situations more difficult to treat (i.e.,
LDL-C goal will be met in almost all patients at non-HDL-
C target).4
Relationships between lipoprotein values were deter-
mined by Pearson and Spearman (if non-normal distribu-
tion) correlation coefficients. We then categorized subjects
by CV risk strata per ATP III guidelines4 and determined the
discordances among patients deemed to be at target goals
for non-HDL-C and for apoB (κ value). The impact of using
several different hypothetical apoB goals was investigated
based upon targets proposed elsewhere.8,12
The main study results that were evaluated are what
would be our indicated next course of action among these
patients seen on their first visit based upon the 2 different
treatment algorithms. Outcomes following the ATP III
guideline algorithm: patients would be deemed potential
candidates for more aggressive treatment, per ATP III, if
non-HDL-C was elevated, but apoB was at goal; and for
less aggressive treatment per ATP III if non-HDL-C was
at goal, but apoB was elevated. Outcomes following the
apoB-based algorithm: patients would be deemed potential
candidates for more aggressive treatment, per apoB, if apoB
was elevated, but non-HDL-C was at goal; and for less
aggressive treatment per apoB if apoB was at goal, but
non-HDL-C was elevated.
Results
There were 125 subjects who had all lipid parameters mea-
sured (Table 1). As these were patients initially referred to
us for complex lipid disorders, many patients had not yet met
ATP III goals despite most taking medications on the first
visit. For the entire population, the non-HDL-C and apoB
were moderately well-correlated (r = 0.47; p<0.001). Similar
to previous reports, however, there was only a fair concor-
dance between them when categorizing whether or not
individuals have met their lipids goals based upon their CV
risk status (κ = 0.22).7 The concordance analysis was based
upon standard apoB goals (bold values in Table 2),8,12 but
did not substantially vary when using different target values.
Once TG levels are elevated (>150 mg·dl−1), non-HDL-C
may be a more appropriate target in all patients to reduce
CV risk. Our main results show that among such new
patients referred to us, between 12%–42% of patients with
a high non-HDL-C actually have apoB at goal for their
level of CV risk (Table 2). These patients would be treated
less aggressively per the apoB algorithm. The results
were similar when excluding patients with very high TG
values defined as >1,000 mg·dl−1 or >500 mg·dl−1, as they
may require more treatment solely to reduce the risk of
developing pancreatitis. However, ATP III guidelines only
specifically suggest targeting non-HDL-C goals based upon
the outlined risk factor categories solely in patients with
TG values between 200 and 499 mg·dl−1. As this TG range
included the majority of our patients previous analyses
(excluded 8 patients), it is important to note that all results
(all percentages in Tables 2 and 3) were not substantively
different if the analyses were carried out only within this
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Table 1. Patient Characteristics of the Entire Cohort Stratified by Risk
Total group Low risk Intermediate risk High risk
n= 125 n= 44 (35%) n= 34 (27%) n= 47 (38%)
Demographics
Age (years) 50±13 45±13 53±12 51±12
Sex (M/F) 57 F 27 F 12 F 18 F
68 M 17 M 22 M 29 M
BMI (kg·m−2) 30±8 27±5 28±5 36±9
Lipids (mg·dl−1)
LDL-C 131±58 144±59 137±60 115±51
HDL-C 46±26 59±38 36±10 40±14
Triglyceride 350±421 272±323 316±387 449±506
Non-HDL-C 192±66 195±64 191±52 191±76
ApoB 119±35 126±38 119±34 111±32
ApoA 132±45 147±60 122±22 123±37
Medications (#pts)
Statins 44 9 11 24
Ezetemibe 31 10 8 13
Niacin 16 3 5 8
Resins 30 4 7 19
Fibrates 11 3 1 7
Fish oils 19 3 5 11
All values are mean±standard deviation Low risk = <2 risk factors and no CV disease or risk equivalents4 Intermediate risk = ≥2 risk factors and no CV
disease or risk equivalents4 High risk= CV disease, risk equivalents, and/or a Framingham risk score ≥204. Abbreviations: BMI, body mass index; LDL-C,
low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; ApoB, apoprotein B100; ApoA, Apoprotein A.
more limited specific population that directly accords with
ATP III guidelines.
The results also confirmed the more commonly reported
finding that a different subset of subjects would be treated
more aggressively per the apoB algorithm.8 Between
44%–50% of patients with non-HDL-C at goal do not
have apoB at goal (Table 3). Between both subsets of
patients, >50% of all subjects would have been treated
either more or less aggressively following an apoB-
based therapeutic algorithm compared with non-HDL-C
algorithm. This is the case whether strictly following ATP III
guidelines (including only patients with TG values between
200–499 mg·dl−1 in the study), or including all patients
with high TG levels (more liberally defined as all patients
with TG values >150 mg·dl−1, between 150–500 mg·dl−1,
or between 150–1,000 mg·dl−1).
Discussion
The apoB has been shown to be a superior CV risk predictor
in most scenarios by some epidemiological studies and is
often discordant to both LDL-C and non-HDL-C.1,6–10 We
have shown this discordance to be present specifically within
our unique cohort of patients with hypertriglyceridemia
referred to a specialty care lipid clinic. The results confirmed
previous reports showing that a therapeutic algorithm based
upon apoB can identify a sizeable group of undertreated
individuals by using non-HDL-C goals.8 While this is true,
we have further highlighted an underrecognized group of
patients. Among those with hypertriglyceridemia (defined
by several different thresholds and ranges) and non-HDL-
C above ATP III targets (even specifically in patients
with TG values only between 200–499 mg·dl−1), there
also exists a sizeable portion who have already achieved
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Clinical Investigations continued
Table 2. Patients with apoB at Goal Despite Having Elevated Triglycerides
(≥ 150 mg·dl−1) and Elevated Non-HDL Cholesterol
Non-HDL and
triglycerides
elevated Non-HDL and triglycerides
All subjects (n= 125) (#patients) elevated AND apoB at goal
Risk Category
apoB cut point #patients
Low (n= 44) 12 ≤110 4 (33%)
≤120 5 (42%)
Intermediate (n= 34) 17 ≤90 1 (6%)
≤105 4 (24%)
≤110 6 (35%)
High (n= 47) 31 ≤80 2 (6%)
≤90 4 (12%)
Non-HDL-C goals defined per ATP III guidelines: low (<2 risk factors),
intermediate (≥2 risk factors without cardiovascular disease or any risk
equivalent), andhigh risk (cardiovasculardisease,any riskequivalent, or
aFraminghamriskscore≥20%)with targets<190, 160,and130 mg·dl−1,
respectively. Primary outcome apoB goals derived from guidelines and
the literature.8,12 Abbreviations: HDL, high density lipoprotein; HDL-C,
high density lipoprotein cholesterol; ApoB, apoprotein B100.
apoB goal. Thus, if we are to propose using an apoB-based
treatment algorithm in the future to guide our subsequent
management of new patients with elevated TG values, the
majority (>50%) would receive different recommendations
from ATP III. This has important implications for us,
and potentially (if corroborated) for other referral-based
specialty lipid clinics.
The fact that apoB, reflecting the number of atherogenic
lipid particles, often remains elevated despite the overall
cholesterol content of lipoproteins being at goal (i.e., non-
HDL-C) is well-recognized.8 We have now shown this to
be the case, even among patients with complex lipid dis-
orders referred to our specialty clinic. This discordance
occurred fairly homogeneously among patients at all levels
of overall CV risk (Table 3). Lipoprotein particle numbers
are often more difficult to reduce with medications than is
the overall content of non-HDL-C in the blood.1,4 On the
contrary, there is a reciprocal group with apoB at goal, yet
non-HDL-C elevated. We hypothesize that this may be com-
prised of individuals with a less atherogenic distribution of
TG-rich lipoprotein subfractions. In our patients (Table 2),
Table 3. Patients at each Risk Category with Non-HDL-C at Goal, but an
Elevated apoB
All subjects Non-HDL at goal Non-HDL at goal
(n= 125) (#patients) AND apoB elevated
Risk Category
apoB cut point #patients
Low (n= 44) 24 ≥110 16 (67%)
≥120 12 (50%)




High (n= 47) 9 ≥80 5 (56%)
≥90 4 (44%)
Non-HDL-C goals defined per ATP III guidelines: low (<2 risk factors),
intermediate (≥2 risk factors without cardiovascular disease or any risk
equivalent), andhigh risk (cardiovascular disease, any risk equivalent, or
a Framinghamrisk score ≥20%)with targets <190, 160, and 130mg·dl−1,
respectively. Primary outcome apoB goals derived from guidelines and
the literature.8,12 Abbreviations: HDL, high density lipoprotein; HDL-C,
high density lipoprotein cholesterol; ApoB, apoprotein B100.
most of these individuals appeared to be of lower overall
CV risk. Such cases may occur in the setting of severe
hypertriglyceridemia due to chylomicronemia (e.g., types
I and V hyperlipidemia) or in patients with elevations in
large, less atherogenic, very low density lipoprotein parti-
cles (e.g., some patients with type IV hyperlipidemias).1–3
In such situations, non-HDL-C will be elevated due to high
cholesterol content specifically within fewer numbers of
large lipid particles that are likely to be much less athero-
genic. Epidemiological studies suggest that this situation
carries less CV risk and that apoB is a superior predictor of
future events.9,10 These findings suggest that many patients
in our clinic who would normally be construed as candidates
for more medications based upon standard ATP III guide-
lines, may in actuality, appropriately, avoid this burden by
basing management upon an apoB-based algorithm.
All studies of apoB have been epidemiological or
retrospective observations within clinical trials.10–16 The
actual goals for apoB are not well determined and require
more clarification by outcome studies. Thus, the thresholds
selected for apoB in our study8,12 are relatively arbitrary
and minor adjustments of these values did modestly alter
our results (Tables 2 and 3). Moreover, there are no clinical
trial data confirming that modulating therapy based upon
apoB levels (and disregarding non-HDL-C) leads to equal or
superior patient CV outcomes. For example, it is rational to
expect that since high TG values may not statistically convey
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excess CV risk once apoB is at goal,9 that withholding TG-
lowering medications in this setting would not produce
worse outcomes. However, such a management strategy
requires formal testing and validation from randomized
clinical trials. Additional limitations of this study are
selection biases and the small sample size. Nevertheless,
the major thrust of this study was to purposely evaluate
the potential differences between treatment algorithms
specifically within our unique referral-based cohort prior to
proposing to utilize an apoB-based algorithm in our specialty
lipid clinic. Thus, the observation of outcomes within our
selected patients was actually an a priori rationale for this
study design. In fact, our study is novel in that we focused
solely upon subjects with high TG levels (plus a high non-
HDL-C) in a real world specialty lipid practice and also
because we specifically highlighted the prevalence of the
reciprocal discordance (high TG levels and non-HDL-C, but
with apoB at goal). Our results may not be generalized to the
population as whole, even though much larger studies have
found similar discordances.8 More importantly, however,
these findings need to be confirmed in other specialty lipid
clinics in order to demonstrate the true impact that apoB-
based algorithms may have on patient management if they
are ever to be more broadly recommended by national
guidelines in the future.
An apoB-based algorithm would lead to substantially
different treatment strategies in most patients compared to
non-HDL-C targets, and even specifically ATP III guidelines,
among our patients seen with high TG values in our specialty
lipid clinic. Although many patients would be treated more
aggressively per apoB, as has been demonstrated in larger
population surveys,8 we also identified a sizeable group
that would, on the contrary, be managed less intensely.
Further corroborations of these observations in specialty
clinics are needed. Due to the fact that most patients in
our clinic would be treated differently, it is reasonable to
posit that the actual CV outcome rates of patients following
the 2 treatment algorithms may substantially differ. We
believe, therefore, that a randomized clinical trial basing
lipid targets upon apoB versus conventional goals may be
warranted.
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